Furthermore, further studies should also assess the impact of adjuvant cardiovascular prevention agents, particularly statins, metformin, SGLT-2 inhibitors, and GLP-1 receptor agonists, on primary endpoints of psoriasis (PASI) and surrogate markers of atherosclerotic cardiovascular disease (e.g., endothelial dysfunction). Here, GLP1R is linked to psoriasis.